MLNT - センプラ (Melinta Therapeutics Inc.) センプラ

 MLNTのチャート


 MLNTの企業情報

symbol MLNT
会社名 Melinta Therapeutics Inc (センプラ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 メリンタ・セラピューティクス(Melinta Therapeutics Inc)は、治療用溶液を提供するように設計される新規抗生物質を開発・商品化する。同社の主力製品は、アメリカ食品医薬品局(FDA)が急性細菌性皮膚及び皮膚構造感染症(ABSSSI)の治療に使用することを承認した抗生物質「Baxdela」である。同社には、臨床前・臨床段階の製品の広範なパイプラインがある。このパイプラインには、抗感染薬市場の異なる分野をターゲットにして、多くの重要種類の抗生物質が含まれる   センプラは、米国の製薬会社。細菌感染症、特に呼吸器感染症と慢性ブドウ球菌感染症の治療向けに抗生物質の開発を手掛ける。地域感染型細菌性肺炎の治療用にソリストマイシンを開発し、経口カプセル、点滴、懸濁製剤にて提供。またフシジン酸として知られる抗生物質Takstaを開発し、ブドウ球菌による人工関節感染の経口治療薬として提供する。   Melinta Therapeutics, Inc. operates as a commercial-stage pharmaceutical company which engages in developing and commercializing anti-infective s for the hospital and selected non-hospital or communities. It markets antibiotics including Baxdela, Vabomere, Orbactiv, and Minocin for injections. These antibiotics are used in the treatment of infections caused by various bacterial diseases. The company was founded by William L. Jorgensen, Peter Moore, and Thomas A. Steitz in October 2000 is headquartered in Morristown, NJ.
本社所在地 300 George Street Suite 301 New Haven CT 06511 USA
代表者氏名 Kevin T. Ferro ケヴィン・T・フェロ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 312-767-0291
設立年月日 38657
市場名 NASDAQ National Market System
ipoyear 2012年
従業員数 300人
url www.cempra.com
nasdaq_url https://www.nasdaq.com/symbol/mlnt
adr_tso
EBITDA EBITDA(百万ドル) -131.68300
終値(lastsale) 4.22
時価総額(marketcap) 236363271.88
時価総額 時価総額(百万ドル) 211.71880
売上高 売上高(百万ドル) 54.99500
企業価値(EV) 企業価値(EV)(百万ドル) 169.09480
当期純利益 当期純利益(百万ドル) -128.23200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Melinta Therapeutics Inc revenues increased from $5.7M to $26.9M. Net loss increased from $35.2M to $85.2M. Revenues reflect Contract revenue increase of 2% to $5.9M. Higher net loss reflects general and administrative increase from $11.1M to $67.5M (expense) Interest expense increase from $469K to $20.9M (expense) Interest Income decrease of 47% to $273K (income).

 MLNTのテクニカル分析


 MLNTのニュース

   Melinta Therapeutics (NASDAQ:MLNT) Stock Price Up 20%  2019/11/17 16:54:53 Modern Readers
Melinta Therapeutics Inc (NASDAQ:MLNT) shares rose 20% during mid-day trading on Friday . The company traded as high as $1.87 and last traded at $1.68, approximately 1,693,700 shares traded hands during trading. An increase of 55% from the average daily volume of 1,090,866 shares. The stock had previously closed at $1.40. MLNT has been the […]
   ValuEngine Upgrades Melinta Therapeutics (NASDAQ:MLNT) to “Buy”  2019/11/16 10:17:51 Modern Readers
Melinta Therapeutics (NASDAQ:MLNT) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Thursday, ValuEngine reports. Other equities analysts have also issued research reports about the company. Zacks Investment Research upgraded Melinta Therapeutics from a “hold” rating to a “strong-buy” rating and set a $3.50 […]
   The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing  2019/11/14 13:07:04 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 13.) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bausch Health Companies Inc (NYSE: BHC ) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ) (reacted to its third-quarter results) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) (reacted to its third-quarter results) IGM Biosciences Inc (NASDAQ: IGMS ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Opiant Pharmaceuticals Inc (NASDAQ: OPNT ) ( reported an unexpected profit for its third quarter) Recro Pharma Inc (NASDAQ: REPH ) Seattle Genetics, Inc. (NASDAQ: SGEN ): filed an arbitration demand to settle dispute with DAIICHI SANKYO/S ADR (OTC: DSNKY ).
   Melinta Therapeutics (NASDAQ:MLNT) Stock Price Down 32% After Earnings Miss  2019/11/14 01:36:02 Modern Readers
Melinta Therapeutics Inc (NASDAQ:MLNT) was down 32% during mid-day trading on Wednesday following a weaker than expected earnings announcement. The stock traded as low as $1.03 and last traded at $1.36, approximately 2,346,700 shares changed hands during trading. An increase of 115% from the average daily volume of 1,090,411 shares. The stock had previously closed […]
   Melinta Therapeutics Inc (NASDAQ:MLNT) Sees Significant Growth in Short Interest  2019/11/13 04:21:12 Modern Readers
Melinta Therapeutics Inc (NASDAQ:MLNT) saw a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 1,920,000 shares, a growth of 17.8% from the September 30th total of 1,630,000 shares. Based on an average daily volume of 445,000 shares, the short-interest ratio is presently 4.3 days. […]
   Melinta Therapeutics (NASDAQ:MLNT) Stock Price Up 20%  2019/11/17 16:54:53 Modern Readers
Melinta Therapeutics Inc (NASDAQ:MLNT) shares rose 20% during mid-day trading on Friday . The company traded as high as $1.87 and last traded at $1.68, approximately 1,693,700 shares traded hands during trading. An increase of 55% from the average daily volume of 1,090,866 shares. The stock had previously closed at $1.40. MLNT has been the […]
   ValuEngine Upgrades Melinta Therapeutics (NASDAQ:MLNT) to “Buy”  2019/11/16 10:17:51 Modern Readers
Melinta Therapeutics (NASDAQ:MLNT) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Thursday, ValuEngine reports. Other equities analysts have also issued research reports about the company. Zacks Investment Research upgraded Melinta Therapeutics from a “hold” rating to a “strong-buy” rating and set a $3.50 […]
   The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing  2019/11/14 13:07:04 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 13.) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bausch Health Companies Inc (NYSE: BHC ) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ) (reacted to its third-quarter results) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) (reacted to its third-quarter results) IGM Biosciences Inc (NASDAQ: IGMS ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Opiant Pharmaceuticals Inc (NASDAQ: OPNT ) ( reported an unexpected profit for its third quarter) Recro Pharma Inc (NASDAQ: REPH ) Seattle Genetics, Inc. (NASDAQ: SGEN ): filed an arbitration demand to settle dispute with DAIICHI SANKYO/S ADR (OTC: DSNKY ).
   Melinta Therapeutics (NASDAQ:MLNT) Stock Price Down 32% After Earnings Miss  2019/11/14 01:36:02 Modern Readers
Melinta Therapeutics Inc (NASDAQ:MLNT) was down 32% during mid-day trading on Wednesday following a weaker than expected earnings announcement. The stock traded as low as $1.03 and last traded at $1.36, approximately 2,346,700 shares changed hands during trading. An increase of 115% from the average daily volume of 1,090,411 shares. The stock had previously closed […]
   Melinta Therapeutics Inc (NASDAQ:MLNT) Sees Significant Growth in Short Interest  2019/11/13 04:21:12 Modern Readers
Melinta Therapeutics Inc (NASDAQ:MLNT) saw a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 1,920,000 shares, a growth of 17.8% from the September 30th total of 1,630,000 shares. Based on an average daily volume of 445,000 shares, the short-interest ratio is presently 4.3 days. […]
   Melinta Therapeutics (NASDAQ:MLNT) Stock Price Up 20%  2019/11/17 16:54:53 Modern Readers
Melinta Therapeutics Inc (NASDAQ:MLNT) shares rose 20% during mid-day trading on Friday . The company traded as high as $1.87 and last traded at $1.68, approximately 1,693,700 shares traded hands during trading. An increase of 55% from the average daily volume of 1,090,866 shares. The stock had previously closed at $1.40. MLNT has been the […]
   ValuEngine Upgrades Melinta Therapeutics (NASDAQ:MLNT) to “Buy”  2019/11/16 10:17:51 Modern Readers
Melinta Therapeutics (NASDAQ:MLNT) was upgraded by investment analysts at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Thursday, ValuEngine reports. Other equities analysts have also issued research reports about the company. Zacks Investment Research upgraded Melinta Therapeutics from a “hold” rating to a “strong-buy” rating and set a $3.50 […]
   The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing  2019/11/14 13:07:04 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 13.) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bausch Health Companies Inc (NYSE: BHC ) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ) (reacted to its third-quarter results) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) (reacted to its third-quarter results) IGM Biosciences Inc (NASDAQ: IGMS ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Opiant Pharmaceuticals Inc (NASDAQ: OPNT ) ( reported an unexpected profit for its third quarter) Recro Pharma Inc (NASDAQ: REPH ) Seattle Genetics, Inc. (NASDAQ: SGEN ): filed an arbitration demand to settle dispute with DAIICHI SANKYO/S ADR (OTC: DSNKY ).
   Melinta Therapeutics (NASDAQ:MLNT) Stock Price Down 32% After Earnings Miss  2019/11/14 01:36:02 Modern Readers
Melinta Therapeutics Inc (NASDAQ:MLNT) was down 32% during mid-day trading on Wednesday following a weaker than expected earnings announcement. The stock traded as low as $1.03 and last traded at $1.36, approximately 2,346,700 shares changed hands during trading. An increase of 115% from the average daily volume of 1,090,411 shares. The stock had previously closed […]
   Melinta Therapeutics Inc (NASDAQ:MLNT) Sees Significant Growth in Short Interest  2019/11/13 04:21:12 Modern Readers
Melinta Therapeutics Inc (NASDAQ:MLNT) saw a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 1,920,000 shares, a growth of 17.8% from the September 30th total of 1,630,000 shares. Based on an average daily volume of 445,000 shares, the short-interest ratio is presently 4.3 days. […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 センプラ MLNT Melinta Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)